Indivior Pharmaceuticals, Inc.

Listed Company

INDVCIK 0001625297NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareGBFY ends Dec 31

Period

FY 2025

Revenue

$1.24B

Net Income

$210.00M

Total Assets

$1.20B

Equity

$-98.00M

Shares Out

121.92M

Op. Cash Flow

$-27.00M

Business

INDIVIOR PLC is a global pharmaceutical company that develops and commercializes medicines to treat substance use disorders, with a focus on opioid use disorder. Its main products include SUBLOCADE (monthly buprenorphine injection), SUBOXONE Film and Tablets (buprenorphine/naloxone), SUBUTEX Tablets (buprenorphine) and OPVEE nasal spray for opioid overdose reversal, alongside advocacy, education and patient support services. Key business activities comprise commercial operations (specialty sales to health systems and criminal justice settings), research and development of pipeline candidates, and manufacturing and global compliance functions. The Company markets and distributes medicines primarily in the U.S. and also in Europe, Canada, Australia and through partners in more than 30 countries.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Net revenue	1,239	1,188	1,093	901
Cost of sales	246	231	174	151
Gross profit	994	957	919	749
Selling, general and administrative	634	612	565	469
Research and development	97	107	116	74
Acquired in-process research and development	0	1	162	0
Litigation settlement	3	195	239	296
Other operating (income) expense, net	−3	4	−9	−8
Operating income (loss)	262	38	−152	−81
Interest income	−22	−23	−43	19
Interest expense	45	41	35	−27
Income (loss) before income taxes	239	20	−145	−89
Income tax expense (benefit)	29	13	−19	44
Net income (loss)	210	7	−126	−44
Basic (in dollars per share)	1.68	0.05	−0.92	−0.32
Diluted (in dollars per share)	1.64	0.05	−0.92	−0.32
Basic (in shares)	125	132	137	139
Diluted (in shares)	128	133	137	139

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	195	319	316	—	—
Short-term investments	0	1	94	—	—
Accounts receivable, net of allowances of $4 (2025) and $3 (2024)	253	254	254	—	—
Inventories	153	167	126	—	—
Prepaid expenses	34	31	—	—	—
Current tax receivable	2	33	0	—	—
Other current assets	16	21	—	—	—
Total current assets	652	827	1,257	—	—
Long-term investments	28	27	41	—	—
Property, plant and equipment, net	144	100	84	—	—
Operating lease right of use assets, net	26	39	40	—	—
Goodwill and other intangible assets, net	2	6	13	—	—
Deferred tax assets	323	277	286	—	—
Other noncurrent assets	27	39	36	—	—
Total assets	1,201	1,316	1,758	—	—
Accrued rebates and product returns	582	562	535	—	—
Accounts payable and accrued expenses	250	216	195	—	—
Accrued litigation settlement expenses, current	42	99	492	—	—
Current portion of long-term debt	29	18	3	—	—
Operating lease liabilities, current	10	10	9	—	—
Income taxes payable	2	7	8	—	—
Other current liabilities	0	11	40	—	—
Total current liabilities	914	924	1,281	—	—
Long-term debt, less current portion	290	315	237	—	—
Accrued litigation settlement expenses, noncurrent	52	365	359	—	—
Operating lease liabilities, noncurrent	22	32	34	—	—
Other noncurrent liabilities	21	18	31	—	—
Total liabilities	1,300	1,652	1,942	—	—
Commitments and contingencies (Note 16)	—	—	—	—	—
Common stock, par value $0.50 per share Issued shares: 125 (2025) and 125 (2024)	62	62	68	—	—
Additional paid-in capital	112	90	88	—	—
Share repurchase commitment	0	−10	−23	—	—
Accumulated other comprehensive loss	−30	−36	−30	—	—
Accumulated deficit	−243	−443	−288	—	—
Total stockholders' deficit	−98	−337	−184	−15	121
Total liabilities and stockholders' deficit	1,201	1,316	1,758	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Depreciation and amortization	10	16	15	16
Amortization of right-of-use assets	10	12	0	—
Stock-based compensation expense	26	24	21	16
Impairment of tangible and intangible assets	19	8	0	0
Unrealized loss on equity investments	0	9	0	0
Deferred income taxes	−46	7	−64	−105
Impact from foreign exchange movements	1	−2	−10	−4
Accounts receivable	3	−1	−33	−21
Current inventories	18	−43	−6	−30
Other current and noncurrent assets	49	377	−418	69
Accrued legal and settlement expenses	−368	−387	50	197
Other current and noncurrent liabilities	41	8	110	−97
Net cash (used in) provided by operating activities	−27	36	−300	−4
Purchases of property and equipment	−66	−29	−8	−5
Purchases of in-process research and development and intangible assets	−1	−2	−45	0
Acquisitions, net of cash acquired	0	0	−129	0
Purchases of investments in debt securities	−20	−17	−45	−245
Sales of equity securities	1	0	0	—
Sales and maturities of debt securities	19	117	129	27
Other proceeds from investing activities	0	0	3	1
Net cash (used in) provided by investing activities	−66	69	−95	−222
Proceeds from the issuance of common stock	2	3	3	2
Cash paid for repurchases of common stock	−11	−173	−33	−90
Proceeds from debt, net	0	332	0	0
Repayments of debt	−17	−240	−12	−3
Transaction costs related to debt refinancing	0	−2	0	—
Settlement of tax on equity awards	−5	−22	−22	−10
Net cash used in financing activities	−30	−102	−64	−101
Net (decrease) increase in cash and cash equivalents	−124	3	−459	−327
Exchange differences	−1	0	1	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro